Italfarmaco Spa

Chemi S.p.a.

Paolo Mascagni

Massimo Pinori

Flavio Leoni

Gianluca Fossati

Giuseppe Bottoni

Giorgio Bertolini

Gianni Gromo

Maria Lattanzio

Daniela Modena

Barbara Vergani

Valentina Saccone

Silvia Consalvi

Pier Lorenzo Puri

Mauro Biffi

Tiziano Oldoni

Roberta Artico

Jacques Mizrahi

Rocco Mazzaferro

Charles A Dinarello

Oreste Piccolo

Silvana Cappelletti

Patrizia Caretto

Marco Adami

Gianfranco Pavich

Christian Steinkühler

Andrea Stevenazzi

Fabrizio Marcucci

Flavio Somenzi

Giovanni Sandrone

Francesco Autuori

Carlo Bianchini

Valmen Monzani

Giuseppe Colombo

Silvio Agozzino

Alessandro Rambaldi

Maria Letizia Marchetti

Paola Giuliani

Maria Valmen Monzani

Andrea Vitali

Pierluigi Lucietto

Tiziano Barbui

Silvia Puccianti

Daniele Barbareschi

Jaime Moscoso

Samuele Pietro Pozzi

Carmine D'urzo

Joseê Golay

Physically and chemically stable oral liquid formulations of Givinostat (Diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride) are disclosed, together with methods for the preparation thereof. Such oral formulations are in the form of aqueous suspensions and contain Givinostat and/or pharmaceutically acceptable salts and/or derivatives thereof, at least a wetting agent and/or at least a density-imparting agent. Such formulations are suitable for oral administration for systemic therapeutic action.

Physically and chemically stable oral suspensions of givinostat

The present invention relates to new benzo-N-hydroxy amide compounds of formula (I) and pharmaceutically acceptable salts, isomers and prodrugs thereof, which show a significant inhibitory activity on the proliferation of tumor cells and specifically of cancer stem cells. 

Benzo-N-hydroxy amide compounds having antitumor activity

The present invention relates to a method for treating muscular dystrophy which comprises administering diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride or other pharmaceutically acceptable salts and/or solvates thereof to a patient in need of such a treatment. The invention further relates to a method for treating muscular dystrophy which comprises administering diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride or other pharmaceutically acceptable salts and/or solvates thereof in combination with one or more additional anti-inflammatory active agents to a patient in need of such a treatment.

Diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride for use in the treatment of muscular dystrophy

Method of treating Philadelphia-negative myeloproliferative syndromes in a patient suffering from such syndromes. The method is carried out by administering to the patient diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl -methyl]-ammonium chloride, or other pharmaceutically acceptable salts and/or solvates, in a daily dosage amount of from 10 to 150 mg per patient.

Use of histone deacetylase inhibitors for the care of philadelphia-negative myeloproliferative syndromes

Non-selective somatostatin analogues

Physically and chemically stable aqueous oral suspensions of riluzole and manufacturing methods thereof. The suspensions contain riluzole in particle form and at least a wetting agent, preferably a surfactant. Riluzole is present in amounts from about 0.1% to about 20% w/v and has an average particle size lower than 200 &#x3bc;m. The suspensions are devoid of the known local (mouth) anaesthetic effects of riluzole.

Riluzole aqueous suspensions

Compound selected from 4-(2(S)-benzoylamino-3-naphthalen-2-yl-propionylamino)-N-hydroxy-benzamide and benzo[1,3]dioxole-5-carboxylic acid [1(S)-(4-hydroxycarbamoyl-phenylcarbamoyl)-2-naphthalen-2-yl-ethyl]-amide, for use in the treatment of a HIV infection. The compound is administered in combination and/or in temporal proximity with at least one anti-retroviral agent.

Derivatives of N-hydroxybenzamide for treating HIV infections

Method of treating a tumor in a patient in need thereof by administering to the patient an effective amount of 4-[6-(diethylaminomethyl)naphth-2-ylmethyloxycarbamoyl]benzohydrozamic acid.

Use of hydroxamic acid derivatives for the preparation of anti-tumour medicaments

Method for treating Philadelphia-negative myeloproliferative syndromes in a patient in need of such treatment, by administering to the patient diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride or other pharmaceutically acceptable salts and/or solvates thereof, in combination with N-hydroxyurea.

Method for treating Philadelphia-negative myeloproliferative syndromes

Alpha-amino acid derivatives with antiinflammatory activity

The present invention relates to novel compounds, of the general formula (I), the N-oxide forms thereof, the salts thereof with pharmaceutically acceptable acids and the stereochemical isomers thereof, which are useful as antifungal agents; to pharmaceutical compositions containing such compounds as the active ingredient; to methods for the production of said compounds and the associated pharmaceutical compositions. 

Azole derivative useful as antifungal agents with reduced interaction with metabolic cytochromes

A compound having formula (I) and a process for the preparation thereof are described.

Monohydrate hydrochloride of the 4-hydroxycarbamoyl-phenyl)-carbamic acid (6-diethylaminomethyl-naphtalen-2-yl) ester

Compounds of formula (I), inhibit TNF&#x3b1; production and may therefore be useful in the treatment of inflammation, of auto-immune diseases, and of pathological conditions which involve excessive production of that cytokine. The compounds of formula (I) are also inhibitors of the histone deacetylase enzyme and may therefore be useful in tumorous diseases, alone or in association with other anti-tumor active ingredients 

Hydroxamic acid derivatives having anti-inflammatory action

Stable, biologically compatible pharmaceutical compositions in the form of water-in-oil microemulsions (w/o), for the sustained release by parenteral administration of active ingredients which are hydrophilic or are made hydrophilic by suitable derivatization, a process for the preparation of said microemulsions and the use thereof.

Sustained release pharmaceutical compositions for the parenteral administration of hydrophilic compounds

Growing community of inventors

Villasanta, Italy

Paolo Mascagni